Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial

Daunorubicin pharmacokinetics (PK) are characterised by an important inter-individual variability, which raises questions about the optimal dose regimen in patients with acute myeloid leukaemia. The aim of the study is to assess the joint daunorubicin/daunorubicinol PK profile and to define an optim...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Guillaume Drevin, Marie Briet, Caroline Bazzoli, Emmanuel Gyan, Aline Schmidt, Hervé Dombret, Corentin Orvain, Aurelien Giltat, Christian Recher, Norbert Ifrah, Philippe Guardiola, Mathilde Hunault-Berger, Chadi Abbara
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2022-04-01
Serie:	Pharmaceutics
Soggetti:	daunorubicin pharmacokinetics acute myeloid leukaemia modelling
Accesso online:	https://www.mdpi.com/1999-4923/14/4/792
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!